ImmuronFRA:ANWA -2.63%56 OCF Yield % is -41.57 as of Jun. 25, 2026. GuruFocus rates FRA:ANWA with a GF Score™ of 56/100 and a GF Value™ of €5.81 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,419 Biotechnology companies, Immuron ranks worse than 80.9% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Immuron OCF Yield % Related Terms
Immuron OCF Yield % Historical Data
* Premium members only.
The historical data trend for Immuron's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:ANWA vs VRTX, REGN, ALNY: OCF Yield % Comparison
For the Biotechnology subindustry, Immuron's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immuron OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immuron's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Immuron's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immuron (FRA:ANWA) has a OCF Yield % of -41.57 as of Jun. 25, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Immuron and its competitors. According to the industry distribution chart, Immuron ranks #1148 out of 1419 companies in the Biotechnology industry, placing it in the top 80.9%.
Is Immuron's OCF Yield % too high?
Immuron's current OCF Yield % is -41.57. Based on the distribution chart, Immuron ranks #1148 out of 1419 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Immuron has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Immuron's OCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Immuron ranks #1148 out of 1419 companies for OCF Yield %. This places Immuron in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Immuron and its competitors. Immuron's current OCF Yield % is -41.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immuron stock overvalued right now?
Based on GuruFocus' analysis, Immuron (FRA:ANWA) is currently considered Possible Value Trap. The stock's GF Value™ is €5.81, compared to a current price of €0.93 — trading 84.1% below its estimated fair value. The current OCF Yield % is -41.57. Immuron's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Immuron (FRA:ANWA), the current OCF Yield % is -41.57 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immuron (FRA:ANWA) Overvalued in 2026?
Based on GuruFocus' analysis, Immuron stock appears to be undervalued.
The current stock price of €0.93 is trading 84.1% below its estimated GF Value™ of €5.81.
GuruFocus considers Immuron to be Possible Value Trap.
Key valuation signals for FRA:ANWA:
OCF Yield %: -41.57
GF Value™: €5.81 vs. price of €0.93 (84.1% below fair value)
No single metric tells the full story. See the FRA:ANWA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
56GF Score
Get the complete analysis for FRA:ANWA
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ANWA has been successfully added to your 
